“零关税”政策红利惠及更多患者

Core Insights - The "zero tariff" policy for imported pharmaceuticals and medical devices has significantly benefited patients, with over 300 million yuan in import value and nearly 40 million yuan in tax reductions since its implementation [3][4]. Group 1: Policy Implementation - The "zero tariff" policy for imported pharmaceuticals and medical devices is the fourth such policy implemented in Hainan Free Trade Port, following similar policies for raw materials, vehicles, and self-use production equipment [2][3]. - As of October 14, 16 enterprises have qualified for the benefits of the "zero tariff" policy, with a total import value exceeding 300 million yuan [3]. Group 2: Financial Impact - The policy has led to a cumulative reduction of 12.97 million yuan in patient hospitalization costs due to the import of nine types of "zero tariff" medical devices [2][3]. - The total tax reduction from the policy amounts to 39.25 million yuan, showcasing its financial impact on both patients and healthcare institutions [3][4]. Group 3: Operational Efficiency - The average approval time for import applications has been reduced from five working days to one, enhancing operational efficiency [3]. - The integration of blockchain technology allows for real-time synchronization of product information, facilitating quicker customs clearance and data matching between customs and hospitals [3]. Group 4: Future Developments - The Hainan Free Trade Port aims to further enhance the "zero tariff" policy by expanding the tax exemption catalog and exploring new business models such as cross-border medical services and telemedicine [4]. - The region has already completed the "first use in China" for 522 types of international innovative drugs and devices, benefiting over 180,000 patients [4].